PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+14.73%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$352M
AUM Growth
+$352M
(+30%)
Cap. Flow
+$77.6M
Cap. Flow
% of AUM
22.07%
Top 10 Holdings %
Top 10 Hldgs %
34.86%
Holding
100
New
24
Increased
44
Reduced
21
Closed
11
Top Buys
| 1 |
Boston Scientific
BSX
|
$13.5M |
| 2 |
Eli Lilly
LLY
|
$11.4M |
| 3 |
Edwards Lifesciences
EW
|
$6.77M |
| 4 |
Haemonetics
HAE
|
$6.72M |
| 5 |
CVS Health
CVS
|
$6.11M |
Top Sells
| 1 |
Altimmune
ALT
|
$6.55M |
| 2 |
iRhythm Technologies
IRTC
|
$6.08M |
| 3 |
Avantor
AVTR
|
$5.36M |
| 4 |
908 Devices
MASS
|
$3.07M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$2.6M |
Sector Composition
| 1 | Healthcare | 96.37% |
| 2 | Industrials | 1.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Establishment Labs
ESTA
$1.11B
| $829K | 0.24% |
+15,173
| New | +$829K |
|
|
OPNT
77
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
| $823K | 0.23% |
76,530
+898
| +1% | +$9.66K |
|
78
Harvard Bioscience
HBIO
$21.1M
| $782K | 0.22% |
305,353
-46,397
| -13% | -$119K |
|
79
Lexicon Pharmaceuticals
LXRX
$392M
| $729K | 0.21% |
303,614
+53,614
| +21% | +$129K |
|
80
Viridian Therapeutics
VRDN
$1.59B
| $725K | 0.21% |
+35,358
| New | +$725K |
|
81
Travere Therapeutics
TVTX
$1.75B
| $655K | 0.19% |
26,565
+315
| +1% | +$7.77K |
|
82
Codexis
CDXS
$218M
| $638K | 0.18% |
105,319
-98,730
| -48% | -$598K |
|
83
Plus Therapeutics
PSTV
$45.7M
| $590K | 0.17% |
88,335
-13,870
| -14% | -$92.6K |
|
84
Edgewise Therapeutics
EWTX
$1.54B
| $492K | 0.14% |
+50,000
| New | +$492K |
|
85
Alpha Teknova
TKNO
$227M
| $406K | 0.12% |
121,424
+1,427
| +1% | +$4.77K |
|
86
Neuronetics
STIM
$216M
| $273K | 0.08% |
+85,866
| New | +$273K |
|
|
BLRX
87
BioLineRX
BLRX
$15.5M
| $267K | 0.08% |
7,221
+85
| +1% | +$3.14K |
|
|
SIEN
88
DELISTED
Sientra, Inc.
SIEN
| $239K | 0.07% |
37,359
-4,559
| -11% | -$29.2K |
|
|
UBX
89
DELISTED
Unity Biotechnology
UBX
| $160K | 0.05% |
+40,409
| New | +$160K |
|
|
ALLK
90
DELISTED
Allakos
ALLK
| – | – |
-160,376
| Closed | -$502K |
|
|
91
Altimmune
ALT
$325M
| – | – |
-559,755
| Closed | -$6.55M |
|
|
92
Avantor
AVTR
$8.74B
| – | – |
-172,269
| Closed | -$5.36M |
|
93
Health Catalyst
HCAT
$228M
| – | – |
-63,104
| Closed | -$914K |
|
|
94
908 Devices
MASS
$214M
| – | – |
-149,315
| Closed | -$3.07M |
|
95
Phathom Pharmaceuticals
PHAT
$843M
| – | – |
-69,135
| Closed | -$583K |
|
96
Rocket Pharmaceuticals
RCKT
$358M
| – | – |
-26,677
| Closed | -$367K |
|
97
Zymeworks
ZYME
$1.07B
| – | – |
-125,806
| Closed | -$667K |
|
|
EIGR
98
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – |
-1,758
| Closed | -$332K |
|
|
SURF
99
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| – | – |
-115,577
| Closed | -$190K |
|
|
FMTX
100
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| – | – |
-78,603
| Closed | -$542K |
|